Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magenta Therapeutics IncfiledCriticalMagenta Therapeutics Inc
Publication of AR110764A1publicationCriticalpatent/AR110764A1/en
Medicines Containing Material From Animals Or Micro-Organisms
(AREA)
Abstract
Métodos de prevención y tratamiento de una enfermedad de injerto versus huésped y de enfermedades autoinmunes, tales como las debidas a una terapia de transplante, mediante una reducción, o agotamiento, selectiva de células hematopoyéticas a través del uso de conjugados de anticuerpo-fármaco y conjugados de ligando-fármaco que se unen específicamente a CD137. Las composiciones y los métodos que se describen en la presente se pueden usar para tratar una variedad de patologías, que incluyen un trastorno de células madres y otras condiciones de la sangre.Methods of prevention and treatment of graft versus host disease and autoimmune diseases, such as those due to transplant therapy, by selective reduction, or depletion of hematopoietic cells through the use of antibody-drug conjugates and conjugates of ligand-drugs that specifically bind to CD137. The compositions and methods described herein can be used to treat a variety of pathologies, which include a stem cell disorder and other blood conditions.
ARP180100135A2017-01-202018-01-19
COMPOSITIONS AND METHODS FOR THE EXHAUSTION OF CD137 + CELLS
AR110764A1
(en)